Hansa Biopharma — Oktober 2025
-
Jeg mener, selv når produktet er godkendt og lanceringen skal igang, går der 3-5 år man er heldig, før mange af disse selskaber faktisk kan break even og tillige give bevis for at der er en stærk fremtid for produktet.. Hansa var vist i kurs 400 for, var det 5år siden? Blot med udgangspunkt i et stort potentiale.. men det tager evigheder at komme over disken på overbevisende måde.
-
Analyst Consensus på Hansa Biopharma's egen hjemmeside:
Analysts and consensus | Hansa Biopharma
We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.
(www.hansabiopharma.com)
Price target (medianen): SEK 97 og med hele 6 købsanbefalinger (uden Redeye) ..
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind